« Return to News | Study Conduct

UK firms go to Russia to conduct cheaper clinical trials

Tuesday, September 20, 2011 11:13 AM

Britain's fastest-growing bio-technology firms are flocking to Russia to run clinical trials more cheaply and quickly than they can in the West, according to This is MONEY.

The Kremlin is providing generous backing for Rusnano, a nanotechnology venture fund. It is also luring biotech firms in a bid to establish Russia as a leading center for pharmaceutical research and development.

It takes “half the time and one tenth of the cost” to run clinical trials in Russia, according to the boss of Xenetic Biosciences. The London-based firm is developing 12 drugs in Russia with Anglo-Russian collaboration and Rusnano funding.

Scott Maguire, chief executive of Xenetic, said, “Regulators do not take as much time to make a decision in Russia and the data you need to go into a trial is not as extensive as in Britain and the US.”

“More biotechs will consider taking this route. Where else are companies going to get the tens of millions of pounds required to run clinical trials?” said Maguire.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013
Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings
Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving
Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.